Merck/Schering Terminate Respiratory Partnership
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms withdraw NDA for Singulair/Claritin combination.
You may also be interested in...
Merck-Schering Claritin/Singulair Combo “Not Approvable” At FDA
Agency's review of Singulair safety, centered on suicidal thinking and behavior, at issue.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.